192 related articles for article (PubMed ID: 27899388)
1. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function.
Keating M; Dasanu CA
BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27899388
[TBL] [Abstract][Full Text] [Related]
2. Paralytic ileus following "subcutaneous bortezomib" therapy: focus on the clinical emergency-report of two cases.
Mele G; Coppi MR; Melpignano A; Quarta G
Clin Exp Med; 2016 Feb; 16(1):99-101. PubMed ID: 25600700
[TBL] [Abstract][Full Text] [Related]
3. [Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Koda Y; Mori T; Shimizu T; Kato J; Yamane A; Sadahira K; Tsukada Y; Yokoyama K; Hashimoto N; Hattori Y; Okamoto S
Rinsho Ketsueki; 2012 Aug; 53(8):760-4. PubMed ID: 22975816
[TBL] [Abstract][Full Text] [Related]
4. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor.
Perfetti V; Palladini G; Brunetti L; Sgarella A; Brugnatelli S; Gobbi PG; Corazza GR
Eur J Gastroenterol Hepatol; 2007 Jul; 19(7):599-601. PubMed ID: 17556909
[TBL] [Abstract][Full Text] [Related]
5. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
7. [Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma - a case report].
Fukushima T; Iwao H; Sakai T; Sato T; Nakamura T; Nakajima A; Miki M; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Umehara H
Gan To Kagaku Ryoho; 2012 May; 39(5):805-7. PubMed ID: 22584336
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Schmidt-Wolf IG; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2015 Jul; 100(7):964-9. PubMed ID: 25840597
[TBL] [Abstract][Full Text] [Related]
9. Possible case of bortezomib-induced ileus paralytic.
Aravind N; Krishnappa N; Shafiq N; Malhotra P
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38383130
[TBL] [Abstract][Full Text] [Related]
10. High Incidence of Paralytic Ileus After Bortezomib Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients: Report of 2 Cases.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Cid J; Lozano M; Campistol JM; Oppenheimer F
Transplantation; 2015 Nov; 99(11):e170-1. PubMed ID: 26492053
[No Abstract] [Full Text] [Related]
11. Real world experience of bortezomib re-treatment for patients with multiple myeloma at first relapse.
Reyal Y; Popat R; Cheesman S; Rismani A; D'Sa S; Rabin N; Yong K
Br J Haematol; 2017 May; 177(3):495-497. PubMed ID: 27062387
[No Abstract] [Full Text] [Related]
12. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
13. Fatal paralytic ileus following vindesine chemotherapy in a patient with myeloma-associated amyloidosis.
Kanoh T
Eur J Haematol; 1989 Jan; 42(1):108. PubMed ID: 2914591
[No Abstract] [Full Text] [Related]
14. [A clinical analysis of 69 newly diagnosed multiple myeloma patients with renal insufficiency].
An N; Li X; Shen M; Chen SL; Huang ZX
Zhonghua Nei Ke Za Zhi; 2016 Oct; 55(10):764-768. PubMed ID: 27686436
[No Abstract] [Full Text] [Related]
15. The safety of bortezomib for the treatment of multiple myeloma.
Cengiz Seval G; Beksac M
Expert Opin Drug Saf; 2018 Sep; 17(9):953-962. PubMed ID: 30118610
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study.
Kondo M; Hotta Y; Yamauchi K; Sanagawa A; Komatsu H; Iida S; Kimura K
BMC Cancer; 2020 Nov; 20(1):1117. PubMed ID: 33203424
[TBL] [Abstract][Full Text] [Related]
17. Bilateral phrenic nerve palsy induced by subcutaneous bortezomib in a patient with newly diagnosed multiple myeloma: first case reported.
López M; Martínez Lacasa X; Martí JM; Muntañola A; Fernández M; Huertas S; Saumell S; De Diego I; Bustamante G; Mesa A; Canet M; Julià M; Vall-Llovera F
Leuk Lymphoma; 2017 Feb; 58(2):482-484. PubMed ID: 27348085
[No Abstract] [Full Text] [Related]
18. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Merz M; Salwender H; Haenel M; Mai EK; Bertsch U; Kunz C; Hielscher T; Blau IW; Scheid C; Hose D; Seckinger A; Jauch A; Hillengass J; Raab MS; Schurich B; Munder M; Brossart P; Gerecke C; Lindemann HW; Zeis M; Weisel K; Duerig J; Goldschmidt H
Haematologica; 2016 Dec; 101(12):e485-e487. PubMed ID: 27540135
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
[TBL] [Abstract][Full Text] [Related]
20. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.
Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Meltem Akay O; Gülbas Z; Nahi H; Plesner T; Snowden JA; Timurağaoğlu A; Dechow T; Lang A; Tuğlular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
Br J Haematol; 2017 Jul; 178(1):61-71. PubMed ID: 28382618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
